Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area
详细信息 查看全文
- 作者：Jianping Song (1)
Duong Socheat (2)
Bo Tan (1)
Suon Seila (2)
Ying Xu (1)
Fengzhen Ou (1)
Sreng Sokunthea (2)
Leap Sophorn (3)
Chongjun Zhou (1)
Changsheng Deng (1)
Qi Wang (1)
Guoqiao Li (1) - 刊名：Malaria Journal
- 出版年：2011
- 出版时间：December 2011
- 年：2011
- 卷：10
- 期：1
- 全文大小：223KB
- 参考文献：1. World Health Organization, 2010: / World malaria report. Geneva: World malaria report;
2. Roll Back Malaria Partnership: What is malaria? [http://www.rollbackmalaria.org/malariaMessages.html]
3. D'Alessandro U, Buttiens H: History and importance of antimalarial drug resistance. / Trop Med Int Health 2001, 6:845-48. CrossRef
4. Nosten F, Ter Kuile F, Chongsuphajaisiddhi T, Luxemburger C, Webster HK, Edstein M, Phaipun L, Thew KL, White NJ: Mefloquine-resistant falciparum malaria on the Thai-Burmese border. / Lancet 1991, 337:1140-143. CrossRef
5. Ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD, Chongsuphajaisiddhi T, Phaipun L, Webster HK, White NJ: High-dose mefloquine in the treatment of mutidrugs-resistance falciparum malaria. / J Infect Dis 1992, 166:1393-400. CrossRef
6. National Center for Parasitology, Entomology and Malaria Control, Ministry of Health: / Annual National Conference of National Center for Parasitology Entomology and Malaria Control. Phnom Penh, Cambodia; 2003.
7. Roll Back malaria Technical Consultation: / Antimalarial drug combination therapy. Geneva: World Health Organization, WHO/CDS/RBM/2001.35;
8. World Health Organization: / Guidelines for the treatment of malaria. Geneva: WHO; 2006:21-2.
9. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF: Piperaquine: a resurgent antimalarial drug. / Drugs 2005, 65:75-7. CrossRef
10. Nguyen XT, Trieu NT, Nguyen CP, Nguyen XT, Bui D, G Dennis S, Marina C, Michael DE: Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam. / Trop Med Int Health 2009, 14:504-11. CrossRef
11. Song JP, Duong S, Suou S, Thou T, Ses S, Sim Y, Tan B, Li GQ: Clinical research of dihydroartemisinin-piperaquine with uncomplicated falciparum malaria. / Natl Med J China 2003, 83:1099-100.
12. Mey BD, Timothy MED, Sean H, Sandra I, Khim N, Thierry F, Yi P, Chiv L, Doung S: Efficacy and safety of dihydroartemisinin-piperaquine (DHP) in Cambodian children and adults with uncomplicated falciparum malaria. / Clin Infect Dis 2002, 35:1469-476. CrossRef
13. Ezzet F, Van VM, Nosten F, Looareesuwan S, White NJ: Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. / Antimicrob Agents Chemother 2000, 44:697-04. CrossRef
14. Trung TN, Tan B, Van Phuc D, Song JP: A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria. / Chin J Integr Med 2009, 15:189-92. CrossRef
15. Krudsood S, Tangpukdee N, Thanchatwet V, Wilairatana P, Srivilairit S, Pothipak N, Jianping S, Guoqiao L, Brittenham GM, Looareesuwan S: Dose ranging studies of new artemisinin-piperaquine fixed combinations compared to standard regimens of artemisisnin combination therapies for acute uncomplicated falciparum malaria. / Southeast Asian J Trop Med Public Health 2007, 38:971-78.
16. Woodrow CJ, Haynes RK, Krishna S: Artemisinins. / Postgrad Med J 2005, 81:71-8. Review CrossRef
17. World Health Organization: / Guidelines for the treatment of malaria -- 2nd edition. Geneva: WHO; 2010:19-1.
18. World Health Organization: / Assessment and monitoring of antimalarial drug efficacy for the treatment of uncompcicated falciparum malaria. Geneva: WHO; 2003.
19. Denis MB, Tsuyuoka R, Lim P, Lindegardh N, Yi P, Top SN, Socheat D, Fandeur T, Annerberg A, Christophel EM, Ringwald P: Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. / Trop Med Int Health 2006, 11:1800-807. CrossRef
20. Djimdé A, Lefèvre G: Understanding the pharmacokinetics of Coartem. / Malar J 2009, Suppl 1:S4. Review CrossRef
21. White NJ, van Vugt M, Ezzet F: Clinical pharmacokinetics andpharmacodynamics and pharmacodynamics of artemetherlumefantrine. / Clin Pharmacokinet 1999, 37:105-25. CrossRef
22. Tan B, Song JP, He YQ, Guo WZ, Guo XB, Li GQ: Tolerance of oral artemisinin piperaquine tablets in Chinese healthy volunteers. / Chin J Clin Pharmacol 2009, 25:405-07.
23. Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, van Doren W, Ngamije D, D'Alessandro U: Safety and efficacy of dihydroartemisinin/piperaquine (DHP) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. / Trans R Soc Trop Med Hyg 2006, 100:1105-011. CrossRef
24. Tangpukdee N, Krudsood S, Thanachartwet W, Chalermrut K, Pengruksa C, Srivilairit S, Silachamroon U, Wilairatana P, Phongtananant S, Kano S, Looareesuwan S: An open randomized clinical trial of Artekin(DHP) vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria. / Southeast Asian J Trop Med Public Health 2005, 36:1085-091.
25. Denis MB, Davis TM, Hewitt S, Incardona S, Nimol K, Fandeur T, Poravuth Y, Lim C, Socheat D: Efficacy and safety of dihydroartemisinin-piperaquine (DHP) in Cambodian children and adults with uncomplicated falciparum malaria. / Clin Infect Dis 2002, 35:1469-476. CrossRef
26. Jinrong W, Xinggang W, Zijian L, Yan L: Malaria prevention survey for administration dihydroartemisinin piperaquine by officers and soldiers stationed in Sudan. / Prac J Med & Pharm 2009, 26:36-7.
27. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, Denis MB, Lim C, Socheat D: Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. / Br J Clin Pharmacol 2004, 57:253-62. CrossRef
28. Jinbo G, Zijian F, Huazhong L, Canjun Zh, Jun G, Gang Zhu, Fanghong Y, Dongshan Zhu: Analysis of side effects caused by piperaquine phosphate for malaria prophylaxis in population. / China Trop Med 2008, 8:541-43.
29. Brockman A, Paul RE, Anderson TJ, Hackford I, Phaiphun L, Looareesuwan S, Nosten F, Day KP: Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. / Am J Trop Med Hyg 1999, 60:14-1. - 作者单位：Jianping Song (1)
Duong Socheat (2)
Bo Tan (1)
Suon Seila (2)
Ying Xu (1)
Fengzhen Ou (1)
Sreng Sokunthea (2)
Leap Sophorn (3)
Chongjun Zhou (1)
Changsheng Deng (1)
Qi Wang (1)
Guoqiao Li (1)
1. Research Center for Qinghao (Artemisia annual L.), Guangzhou University of Chinese Medicine, Guangzhou, China
2. National Centre for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia
3. Pursat Referral Hospital, Pursat, Cambodia
文摘
Background Drug resistance of falciparum malaria is a global problem. Sulphadoxine/pyrimethamine-resistant and mefloquine-resistant strains of falciparum malaria have spread in Southeast Asia at lightning speed in 1980s-1990s, and the Cambodia-Thailand border is one of the malaria epidemic areas with the most severe forms of multi-drug resistant falciparum malaria. Methods Artemisinin-piperaquine (AP), dihydroartemisinin-piperaquine phosphate (DHP) and artemether-lumefantrine (AL) were used to treat 110, 55 and 55 uncomplicated malaria patients, respectively. The total dosage for adults is 1,750 mg (four tablets, twice over 24 hours) of AP, 2,880 mg (eight tablets, four times over two days) of DHP, and 3,360 mg (24 tablets, six times over three days) of AL. The 28-day cure rate, parasite clearance time, fever clearance time, and drug tolerance of patients to the three drugs were compared. All of the above methods were consistent with the current national guidelines. Results The mean parasite clearance time was similar in all three groups (66.7 ± 21.9 hrs, 65.6 ± 27.3 hrs, 65.3 ± 22.5 hrs in AP, DHP and AL groups, respectively), and there was no remarkable difference between them; the fever clearance time was also similar (31.6 ± 17.7 hrs, 34.6 ± 21.8 hrs and 36.9 ± 15.4 hrs, respectively). After following up for 28-days, the cure rate was 95.1%(97/102), 98.2%(54/55) and 82.4%(42/51); and the recrudescence cases was 4.9%(5/102), 1.8%(1/55) and 17.6%(9/51), respectively. Therefore, the statistical data showed that 28-day cure rate in AP and DHP groups was superior to AL group obviously. The patients had good tolerance to all the three drugs, and some side effects (anoxia, nausea, vomiting, headache and dizziness) could be found in every group and they were self-limited; patients in control groups also had good tolerance to DHP and AL, there was no remarkable difference in the three groups. Conclusions AP, DHP and AL all remained efficacious treatments for the treatment of falciparum malaria in Cambodia-Thailand border area. However, in this particular setting, the AP regimen turned out to be favourable in terms of efficacy and effectiveness, simplicity of administration, cost and compliance. Trial Registration The trial was registered at Chinese Clinical Trial Register under identifier 2005L01041.